
An in-depth review of mechanisms linked to the pathogenesis of Alzheimer disease, including amyloid and tau.

An in-depth review of mechanisms linked to the pathogenesis of Alzheimer disease, including amyloid and tau.

On the first ever #DocTalk a trio of expert physicians weighed in on what drives the US drug shortage problem.

A new study links high levels of high‐sensitivity cardiac troponin T and N‐terminal pro‐B‐type natriuretic peptide to an increase in fall risk for geriatric adults.

Age-adjusted rates of drug overdose deaths have increased nearly five-fold in less than 2 decades.

George Bakris, MD, outlines the difficulties clinicians face when treating diabetic kidney disease in an aging population.

Ronald C. Petersen, MD, PhD, discusses the relationship between genetics and the risk for developing Alzheimer disease, as well as highlights efforts of the Generation Program.

How improved telemedicine options could benefit the geriatric patient population and others who may not actually be suitable for emergency care situations.

The meta-analysis was comprised of 402 individual studies in which the primary therapy was 1 of 32 antipsychotics.

A recent study of more than 200,000 injured workers identified risk factors of opioid use of a previously opioid-free population.

A new study has found that both systolic and diastolic blood pressure independently influenced the risk of adverse cardiovascular events.

A recent analysis of the IMPROVE-IT results found that simvastatin-ezetimibe was associated with greater reductions in LDL-C and lower rates of MI, stroke and CVD than simvastatin monotherapy.

The Erchonia Corp. product reportedly reduced patient pain by nearly 50% in clinical trials.

After a decade-plus, the risk management reduction program is not associated with a direct drop in at-risk pregnancies.

New evidence from a cumulative RCT analysis suggests irritable bowel syndrome patients do not definitively benefit from FMT treatment.

Merck announced the FDA's approval of their NDA for imipenem, cilastatin, and relebactam (Recarbrio) on Wednesday morning.

A new assessment of prevalence studies shows some countries could have an OSA prevalence rate of more than half their entire population.

Study from investigators in London found that high iron levels were associated with a lower risk of high cholesterol levels and reductions in atherosclerosis, but these same high levels were also associated with increased risk of stroke.

Former Vice President Joe Biden's presidential campaign has resulted in the nonprofit organization's indefinite suspension.

Investigators comparing New York and a group of control states before and after mandates found greater than expected reductions of in-hospital mortality.

The majority of physicians who exhibit burnout symptoms receive more than the average number of system-generated in-basket messages.

How the thought of AD has changed to interpret the disease's pathology, and why that has benefitted clinicians.

AD symptoms can take years to manifest, making clinical trials difficult. Investigators are fixed on finding disease biomarkers.

A trio of emergency medicine experts headline our first entry in the weekly healthcare conversation on Twitter.

Recent study shows that obesity appears to be associated with an increased pediatric MS risk and that obese patients did not respond well to first-line medications.

Investigators examined more than 3500 adolescents and found associations between computer and social media use, but not video game and television use.

Professor of medicine at Harvard Medical School discusses how much progress has been made in the fight against cardiovascular disease.

Study of more than 650 COPD patients found that CRP-guided prescribing resulted in a lower percentage of patients who reported antibiotic use.

Leading a healthy lifestyle can decrease a person's risk of dementia, even if a patient already has a high genetic risk, according to a new study.

Combination of ibuprofen and Percocet found to reduce patient opioid consumption following surgery compared to receiving opioids alone.

Investigators found that galcanezumab reduced frequency of cluster headache attacks and had no substanial differences in adverse events when compared to placebo.